Outcomes in COVID-19 DFV890 studies

All studies   Mortality   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -3% 1 142 Improvement, Studies, Patients Relative Risk Mortality -3% 1 142 RCTs -3% 1 142 Late -3% 1 142 DFV890 for COVID-19 c19early.org November 2025 FavorsDFV890 Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Madurka (RCT) -3% 1.03 [0.41-2.59] death 8/70 8/72 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.96 Late treatment -3% 1.03 [0.41-2.59] 8/70 8/72 3% higher risk All studies -3% 1.03 [0.41-2.59] 8/70 8/72 3% higher risk 1 DFV890 COVID-19 study c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.96 Effect extraction pre-specified(most serious outcome) Favors DFV890 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Madurka (RCT) -3% 1.03 [0.41-2.59] 8/70 8/72 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.96 Late treatment -3% 1.03 [0.41-2.59] 8/70 8/72 3% higher risk All studies -3% 1.03 [0.41-2.59] 8/70 8/72 3% higher risk 1 DFV890 COVID-19 mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.96 Favors DFV890 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Madurka (RCT) -3% 1.03 [0.41-2.59] death 8/70 8/72 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.96 Late treatment -3% 1.03 [0.41-2.59] 8/70 8/72 3% higher risk All studies -3% 1.03 [0.41-2.59] 8/70 8/72 3% higher risk 1 DFV890 COVID-19 serious outcome c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.96 Effect extraction pre-specified(most serious outcome) Favors DFV890 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Madurka (RCT) -1% 1.01 [0.74-1.38] no recov. 70 (n) 72 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.95 Late treatment -1% 1.01 [0.74-1.38] 70 (n) 72 (n) 1% higher risk All studies -1% 1.01 [0.74-1.38] 70 (n) 72 (n) 1% higher risk 1 DFV890 COVID-19 recovery result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.95 Favors DFV890 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Madurka (RCT) -3% 1.03 [0.41-2.59] death 8/70 8/72 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.96 Late treatment -3% 1.03 [0.41-2.59] 8/70 8/72 3% higher risk All studies -3% 1.03 [0.41-2.59] 8/70 8/72 3% higher risk 1 DFV890 COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.96 Effect extraction pre-specified(most serious outcome) Favors DFV890 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Madurka (RCT) -3% 1.03 [0.41-2.59] 8/70 8/72 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.96 Late treatment -3% 1.03 [0.41-2.59] 8/70 8/72 3% higher risk All studies -3% 1.03 [0.41-2.59] 8/70 8/72 3% higher risk 1 DFV890 COVID-19 RCT mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.96 Favors DFV890 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Madurka (RCT) -3% 1.03 [0.41-2.59] death 8/70 8/72 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.96 Late treatment -3% 1.03 [0.41-2.59] 8/70 8/72 3% higher risk All studies -3% 1.03 [0.41-2.59] 8/70 8/72 3% higher risk 1 DFV890 COVID-19 peer reviewed studies c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.96 Effect extraction pre-specified(most serious outcome) Favors DFV890 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Madurka (RCT) -3% 1.03 [0.41-2.59] death 8/70 8/72 Improvement, RR [CI] Treatment Control Madurka (RCT) 23% 0.77 [0.28-2.11] death 6/70 8/72 Madurka (RCT) -1% 1.01 [0.74-1.38] no recov. 70 (n) 72 (n) DFV890 COVID-19 outcomes c19early.org November 2025 Favors DFV890 Favors control